NorthWest Biotherapeutics Inc (NWBO)

[Slave1]

Thanks, Doc Logic, appreciate the thoughtful expansion. Just to clarify, I wasn’t referencing Fraunhofer or German regulatory restrictions specifically, but I agree with your broader point: once statistical sufficiency was reached, continuing SOC-only enrollment would have raised ethical concerns. I also completely agree that artisan manufacturing was never viable for a scalable platform, and the recent regulatory shifts (like PICV and IFR) are finally aligning with what the platform was always designed to be.